- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Patent holdings for IPC class A61K 31/513
Total number of patents in this class: 3562
10-year publication summary
|
273
|
273
|
304
|
337
|
315
|
291
|
378
|
310
|
312
|
71
|
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1808 |
86 |
| Taisho Pharmaceutical Co., Ltd. | 844 |
56 |
| Merck Sharp & Dohme LLC | 3689 |
52 |
| Gilead Sciences, Inc. | 1879 |
49 |
| Takeda Pharmaceutical Company Limited | 2961 |
45 |
| Corcept Therapeutics, Inc. | 284 |
43 |
| Immunomedics, Inc. | 290 |
36 |
| Bristol-myers Squibb Company | 5080 |
32 |
| F. Hoffmann-La Roche AG | 7958 |
30 |
| The Regents of the University of California | 18943 |
27 |
| Genentech, Inc. | 3742 |
27 |
| Boehringer Ingelheim International GmbH | 4629 |
26 |
| Novartis AG | 11238 |
24 |
| Merck Sharp & Dohme Corp. | 2247 |
23 |
| Isofol Medical AB | 41 |
23 |
| Pfizer Inc. | 3322 |
22 |
| Celgene Quanticel Research, Inc. | 167 |
21 |
| Bayer Pharma AG | 1096 |
20 |
| Kabushiki Kaisha Yakult Honsha | 386 |
20 |
| Merck Patent GmbH | 5909 |
18 |
| Other owners | 2882 |